Drug Profile
Protein kinase inhibitor nanoparticle therapeutic - Amgen/Pfizer
Alternative Names: Kinase Inhibitor Nanomedicine - Amgen/PfizerLatest Information Update: 24 Jan 2017
Price :
$50
*
At a glance
- Originator Amgen; BIND Biosciences
- Developer Amgen; BIND Therapeutics
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 02 Jul 2014 Amgen and BIND Therapeutics terminate terminate their agreement for the protein kinase inhibitor nanoparticle therapeutic
- 02 Jul 2014 Discontinued - Preclinical for Solid tumours in USA (unspecified route)
- 03 Apr 2013 BIND Biosciences is now called BIND Therapeutics